Filter

Refine by Access

Refine by Collections

Refine by Type

Refine by Date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 32 items for :

  • "polycythaemia vera" x
  • Refine by Access: All Content x
Clear All

Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében

Orvosi Hetilap
Volume/Issue:
Volume 157: Issue 44
DOI:
https://doi.org/10.1556/650.2016.30583
Authors:
Imelda Marton
,
Zsófia Simon
, and
Zita Borbényi

thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124 (16), 2507–2513. 2 Tefferi, A.: Polycythemia vera and essential thrombocythemia: 2012 update on

Restricted access

Philadelphia-negatív krónikus Myeloproliferativ Neoplasia Magyarországi Regiszter. Polycythaemia verás betegeink adatainak elemzése

Orvosi Hetilap
Volume/Issue:
Volume 158: Issue 23
DOI:
https://doi.org/10.1556/650.2017.30766
Authors:
Péter Dombi
,
Árpád Illés
,
Judit Demeter
,
Lajos Homor
,
Zsófia Simon
,
Ádám Kellner
,
Éva Karádi
,
Erika Valasinyószki
,
Miklós Udvardy
, and
Miklós Egyed

neoplasms. Eur J Haematol. 2015; 95: 270–279. 3 Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J

Open access

BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera

Physiology International
Volume/Issue:
Volume 110: Issue 3
DOI:
https://doi.org/10.1556/2060.2023.00261
Authors:
Malaz Khodier
and
Klára Gadó

granulocytes, namely neutrophils, though the number of eosinophils and basophils may also be elevated. On the other side, there are the Philadelphia Chromosome negative, or more recently referred to as, the BCR::ABL1- MPNs, which include polycythemia vera (PV

Open access

A Philadelphia-negatív krónikus myeloproliferativ kórképek epidemiológiai jellemzői Szabolcs-Szatmár-Bereg megyében. 33 év adatainak elemzése

Orvosi Hetilap
Volume/Issue:
Volume 158: Issue 15
DOI:
https://doi.org/10.1556/650.2017.30701
Authors:
János Jakó
and
László Szerafin

thrombocythemia and polycythemia vera. Eur. J. Haematol., 2016, 96 (3), 285–290. 32 Szerafin, L., Jakó, J.: Chronic myeloid leukaemia following polycythaemia

Restricted access

Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection

Orvosi Hetilap
Volume/Issue:
Volume 148: Issue 5
DOI:
https://doi.org/10.1556/oh.2007.27860
Authors:
Hajnalka Andrikovics
,
Anikó Szilvási
,
Nóra Meggyesi
,
Viktória Király
,
Gabriella Halm
,
Sándor Lueff
,
Sarolta Nahajevszky
,
Gábor Mikala
,
Andrea Sipos
,
Nóra Lovas
,
Zoltán Csukly
,
Zoltán Mátrai
,
Júlia Tamáska
,
Attila Tordai
, and
Tamás Masszi

Campbell, P. J., Scott, L. M., Buck, G. és mtsai Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 2005, 366 , 1945

Restricted access

Társult tumorok előfordulása akut myeloid leukémiában, krónikus myeloid leukémiában és Philadelphia-negatív krónikus myeloproliferativ betegségekben

Occurrence of associated tumours in acute myeloid leukemia, chronic myeloid leukemia and Philadelphia-negative chronic myeloproliferative disorders

Hematológia–Transzfuziológia
Volume/Issue:
Volume 51: Issue 4
DOI:
https://doi.org/10.1556/2068.2018.51.4.5
Authors:
János Jakó
and
László Szerafin

T. Impact of therapy on the development of second malignancies in essential thrombocythemia and polycythemia vera: Are we comfortable about this? Leuk Lymphoma 2016; 57: 6

Restricted access

Diagnosztikus és terápiás dilemmák polycythaemia verában

Diagnostic and therapeutic dilemmas in polycythaemia vera

Hematológia–Transzfuziológia
Volume/Issue:
Volume 51: Issue 4
DOI:
https://doi.org/10.1556/2068.2018.51.4.3
Authors:
Gyula Reményi
,
Árpád Illés
, and
Miklós Udvardy

Irodalom 1 Dombi P, Illés Á, Demeter J, et al. Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera

Restricted access

Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia

Orvosi Hetilap
Volume/Issue:
Volume 152: Issue 45
DOI:
https://doi.org/10.1556/oh.2011.29226
Authors:
János László Iványi
,
Éva Marton
, and
Márk Plander

polycythemia vera. J. Biol. Chem., 2005, 280 , 22788–22792. Li Z. Identification of an acquired JAK2 mutation in polycythemia vera J. Biol. Chem

Restricted access

Philadelphia-negatív krónikus myeloproliferativ neoplasia regiszter magyarországi létrehozása

Orvosi Hetilap
Volume/Issue:
Volume 157: Issue 3
DOI:
https://doi.org/10.1556/650.2016.30340
Authors:
Péter Dombi
,
Árpád Illés
,
Judit Demeter
,
Lajos Homor
,
Zsófia Simon
,
Miklós Udvardy
, and
Miklós Egyed

. Med., 2013, 369 (25), 2379–2390. 3 Moulard, O., Mehta, J., Fryzek, J., et al.: Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European

Open access

Complex molecular genetic diagnostic algorithm in the diagnosis of myeloproliferative neoplasms

Orvosi Hetilap
Volume/Issue:
Volume 155: Issue 52
DOI:
https://doi.org/10.1556/oh.2014.30051
Authors:
Tünde Krähling
,
Katalin Balassa
,
Nóra Meggyesi
,
András Bors
,
Judit Csomor
,
Árpád Bátai
,
Gabriella Halm
,
Miklós Egyed
,
Sándor Fekete
,
Péter Reményi
,
Tamás Masszi
,
Attila Tordai
, and
Hajnalka Andrikovics

constitutive signalling causes polycythaemia vera. Nature, 2005, 434 (7037), 1144–1148. Kralovics, R., Passamonti, F., Buser, A. S., et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J

Open access
View license